Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 52, Issue 6, Pages 841-844Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.110.084236
Keywords
somatostatin receptors; SPECT/CT; PET/CT; targeted radionuclide therapy; theranostics
Ask authors/readers for more resources
Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [In-111-diethylenetriaminepentaacetic acid(0)] octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as Ga-68, Cu-64, and F-18. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with Y-90 and Lu-177.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available